ZAI LAB LIMITED Income (Loss) from Equity Method Investments
ZAI LAB LIMITED (ZLAB) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2025-02-27
- ZAI LAB LIMITED income (loss) from equity method investments for the quarter ending 2023-12-31 was $0.00.
- ZAI LAB LIMITED income (loss) from equity method investments for the quarter ending 2023-09-30 was $0.00.
- ZAI LAB LIMITED income (loss) from equity method investments for the quarter ending 2023-06-30 was $0.00.
- ZAI LAB LIMITED income (loss) from equity method investments for the quarter ending 2023-03-31 was $0.00.
- ZAI LAB LIMITED income (loss) from equity method investments for fiscal 2024 was $0.00.
- ZAI LAB LIMITED income (loss) from equity method investments for fiscal 2023 was $0.00.
- ZAI LAB LIMITED income (loss) from equity method investments for fiscal 2022 was -$221.00K.
- ZAI LAB LIMITED income (loss) from equity method investments for fiscal 2021 was -$1.06M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month | Income (Loss) from Equity Method Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | -$221.00K 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | -$221.00K 10-Q · filed 2023-11-07 | -$730.00K derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | -$221.00K 10-Q · filed 2023-08-07 | -$730.00K derived: sum of 3 quarters · filed 2024-02-27 | -$1.07M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | -$221.00K 10-Q · filed 2023-05-09 | -$730.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.07M derived: sum of 3 quarters · filed 2024-02-27 | -$1.47M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | -$509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$849.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.25M derived: sum of 3 quarters · filed 2024-02-27 | -$1.06M 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$340.00K 10-Q · filed 2022-11-09 | -$743.00K derived: sum of 2 quarters · filed 2022-11-09 | -$548.00K 10-Q · filed 2022-11-09 | -$996.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$403.00K 10-Q · filed 2022-08-09 | -$208.00K 10-Q · filed 2022-08-09 | -$656.00K derived: sum of 3 quarters · filed 2023-03-01 | -$921.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $195.00K 10-Q · filed 2022-05-10 | -$253.00K derived: sum of 2 quarters · filed 2023-03-01 | -$518.00K derived: sum of 3 quarters · filed 2023-03-01 | -$787.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$713.00K derived: sum of 2 quarters · filed 2023-03-01 | -$982.00K derived: sum of 3 quarters · filed 2023-03-01 | -$1.12M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$265.00K 10-Q · filed 2021-11-09 | -$534.00K derived: sum of 2 quarters · filed 2021-11-09 | -$671.00K 10-Q · filed 2021-11-09 | -$921.25K derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | -$269.00K 10-Q · filed 2021-08-09 | -$406.00K 10-Q · filed 2021-08-09 | -$656.25K derived: sum of 3 quarters · filed 2022-03-01 | -$842.00K derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | -$137.00K 10-Q · filed 2021-05-10 | -$387.25K derived: sum of 2 quarters · filed 2022-03-01 | -$573.00K derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | -$250.25K derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | -$436.00K derived: sum of 2 quarters · filed 2022-03-01 | -$752.00K 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$185.75K derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | -$501.75K 6-K · filed 2020-01-21 | |||
| 2019-06-30 | -$316.00K 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | -$232.74K derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | -$587.00K 10-K · filed 2021-03-01 | -$586.55K 20-F · filed 2019-03-29 | ||
| 2018-09-30 | -$354.26K 6-K · filed 2020-01-21 | ||||
| 2017-12-31 | -$249.65K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |